Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$161.01 - $317.85 $183 Million - $360 Million
1,134,046 New
1,134,046 $359 Million
Q3 2023

Nov 14, 2023

SELL
$164.66 - $218.08 $18.9 Million - $25 Million
-114,729 Reduced 8.19%
1,285,508 $217 Million
Q2 2023

Aug 14, 2023

SELL
$176.32 - $240.22 $36.4 Million - $49.6 Million
-206,617 Reduced 12.86%
1,400,237 $304 Million
Q1 2023

May 12, 2023

BUY
$161.33 - $204.36 $89 Million - $113 Million
551,778 Added 52.3%
1,606,854 $292 Million
Q4 2022

Feb 13, 2023

BUY
$191.53 - $236.82 $10.3 Million - $12.8 Million
53,973 Added 5.39%
1,055,076 $207 Million
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $7.79 Million - $17.5 Million
62,954 Added 6.71%
1,001,103 $225 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $7.97 Million - $12.2 Million
84,812 Added 9.94%
938,149 $119 Million
Q1 2022

May 16, 2022

SELL
$98.9 - $132.37 $14 Million - $18.7 Million
-141,202 Reduced 14.2%
853,337 $108 Million
Q4 2021

Feb 11, 2022

SELL
$110.64 - $159.4 $812,872 - $1.17 Million
-7,347 Reduced 0.73%
994,539 $130 Million
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $5.6 Million - $6.96 Million
55,305 Added 5.84%
1,001,886 $123 Million
Q2 2021

Aug 16, 2021

BUY
$107.45 - $135.95 $31.1 Million - $39.4 Million
289,685 Added 44.1%
946,581 $108 Million
Q1 2021

May 17, 2021

BUY
$95.46 - $133.08 $50 Million - $69.7 Million
523,865 Added 393.79%
656,896 $79 Million
Q4 2020

Feb 12, 2021

BUY
$75.23 - $109.23 $10 Million - $14.5 Million
133,031 New
133,031 $13.5 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.